Skip to main content
SpringerLink
Log in

Cancer therapeutics based on BCL-2 functional conversion

  • Perspective
  • Published:
Apoptosis Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Gupta D, Kumar M, Tyagi P, Kapoor S, Tyagi A, Barman TK, Kharbanda S, Kufe D, Singh H (2018) Concomitant delivery of paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. Nanomed Nanotechnol Biol Med 14(4):1301–1313

    Article  CAS  Google Scholar 

  2. Honma N, Horii R, Ito Y, Saji S, Younes M, Iwase T, Akiyama F (2015) Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. BMC Cancer 15:698

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, Tian X, Town J, Cao X, Lin F et al (2008) A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 14:285–298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kumar M, Gupta D, Singh G, Sharma S, Bhat M, Prashant CK, Dinda AK, Kharbanda S, Kufe D, Singh H (2014) Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res 74:3271–3281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pearce MC, Gamble JT, Kopparapu PR, O’Donnell EF, Mueller MJ, Jang HS, Greenwood JA, Satterthwait AC, Tanguay RL, Zhang X-K, Kolluri SK (2018) Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells. Oncotarget 9:26072–26085

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Laboratory, Department of Environmental & Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA

    Martin C. Pearce & Siva Kumar Kolluri

  2. Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA

    Arnold C. Satterthwait & Xiao-kun Zhang

  3. School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361005, China

    Xiao-kun Zhang

  4. Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA

    Siva Kumar Kolluri

Authors
  1. Martin C. Pearce
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnold C. Satterthwait
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-kun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Siva Kumar Kolluri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Siva Kumar Kolluri.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pearce, M.C., Satterthwait, A.C., Zhang, Xk. et al. Cancer therapeutics based on BCL-2 functional conversion. Apoptosis 24, 1–2 (2019). https://doi.org/10.1007/s10495-018-1504-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-018-1504-5

Search

Navigation